- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka
Retrospective data, Review, Journal: Systematic literature review and network meta-analysis of lurasidone, brexpiprazole and cariprazine for schizophrenia. (Pubmed Central) - Aug 3, 2022
Lurasidone was comparable to brexpiprazole and cariprazine for efficacy and safety outcomes assessed at 6 weeks, with the 160 mg dose being superior for the change in PANSS and CGI-S outcomes. The lurasidone results were relatively consistent across doses compared with brexpiprazole and cariprazine.
- |||||||||| Promacta (eltrombopag) / Novartis
FDA event, Journal: In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus. (Pubmed Central) - Jul 29, 2022
According to the calculations of MM-GBSA, tucatinib (-54.11 kcal/mol) and Promacta (-56.20 kcal/mol) occupied the active site of neuraminidase with a higher binding affinity than the standard drug peramivir (-49.09 kcal/mol)...Therefore, we propose to test these compounds experimentally against the influenza H7N9 virus. The investigation and validation of these potential H7N9 inhibitors would be beneficial in order to bring these compounds into clinical settings.
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Biomarker, Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: NRX-GLX: NRX101 Glx Biomarker Validation Study (clinicaltrials.gov) - Jul 23, 2022
P2/3, N=0, Withdrawn,
The investigation and validation of these potential H7N9 inhibitors would be beneficial in order to bring these compounds into clinical settings. N=24 --> 0 | Trial completion date: Feb 2022 --> Aug 2022 | Active, not recruiting --> Withdrawn | Trial primary completion date: Dec 2021 --> Apr 2022
- |||||||||| lurasidone / Generic mfg.
IPT.03 – Beyond psychosis: effects of lurasidone on other schizophrenia symptoms (Product Theatre [IN-PERSON, ONLINE]) - Jul 23, 2022 - Abstract #ECNP2022ECNP_326;
Disability has been attributed to the combined effects of cognitive, negative and affective symptoms, even after the psychotic symptoms are successfully treated. The objective of this presentation is to share direct clinical experience with the second-generation antipsychotic lurasidone, along with a clinical overview of data from lurasidone controlled studies related to the management of schizophrenia and its various dimensions.
- |||||||||| lithium carbonate ER / Generic mfg.
Can we improve cognition in schizophrenia and bipolar disorder? A practice orientated guide (Hall F2 [IN-PERSON, ONLINE]) - Jul 23, 2022 - Abstract #ECNP2022ECNP_134;
Even lithium, which is the gold standard medication for bipolar disorders, may have protective effects on cognitive functions.As well as information related to the nature and consequences of cognitive deficits, this session will cover putative pro-cognitive therapies for these illnesses, spanning pharmacological and non-pharmacological modalities. Across our illness domains of focus, these include cognitive remediation therapy, functional remediation, lurasidone, vortioxetine and more…. We consider when, as well as how, cognitive enhancement therapies should be implemented and the potential benefits of early cognitive intervention for people with psychotic and bipolar disorders.
- |||||||||| lithium carbonate ER / Generic mfg.
E07 – COG…..IGNITION! Can we jumpstart cognition in schizophrenia and bipolar disorder? (Hall F2 [IN-PERSON, ONLINE]) - Jul 23, 2022 - Abstract #ECNP2022ECNP_128;
Across our illness domains of focus, these include cognitive remediation therapy, functional remediation, lurasidone, vortioxetine and more….We consider when, as well as how, cognitive enhancement therapies should be implemented and the potential benefits of early cognitive intervention for people with psychotic and bipolar disorders.> The Educational Update Session is 80 minutes long: after an Introduction by the moderator (5 minutes), each of the 2 speakers has 30 minutes to present, followed by 5 minutes of Q&A. The last 5 minutes are for the final remarks.
- |||||||||| lithium carbonate ER / Generic mfg.
Putative mechanisms of impaired neurocognition in schizophrenia and bipolar disorder (Hall F2 [IN-PERSON, ONLINE]) - Jul 23, 2022 - Abstract #ECNP2022ECNP_23;
Across our illness domains of focus, these include cognitive remediation therapy, functional remediation, lurasidone, vortioxetine and more…. We consider when, as well as how, cognitive enhancement therapies should be implemented and the potential benefits of early cognitive intervention for people with psychotic and bipolar disorders.
- |||||||||| lurasidone / Generic mfg.
Trial completion date, Trial primary completion date: Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" (clinicaltrials.gov) - Jul 20, 2022
P=N/A, N=300, Recruiting,
Given the essential role of stress responsiveness in almost every life process, the identification of the underlying mechanisms and their potential pharmacological modulation add further translational value to our data. Trial completion date: Apr 2022 --> Dec 2022 | Trial primary completion date: Apr 2022 --> Dec 2022
- |||||||||| risperidone / Generic mfg., lurasidone / Generic mfg., ziprasidone / Generic mfg.
Journal: Investigations into the stability of 17 psychoactive drugs in a "simulated postmortem blood" model. (Pubmed Central) - Jul 17, 2022
However, the 1,2-benzisothiazole antipsychotics, ziprasidone and lurasidone, were found to degrade at a rate comparable to the known labile control, risperidone. In longer experiments (seven to twelve months), where specimens were stored at -20 °C, 4 °C, and ambient temperature, N-dealkylation degradation products were detected for many of the drugs, with greater formation in specimens stored at -20 °C than at 4 °C.
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka, Nuplazid (pimavanserin) / Acadia Pharma
Journal: Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics. (Pubmed Central) - Jun 24, 2022
This cross-sectional assessment of data from FAERs (2004-2021) suggested that users of clozapine, olanzapine, quetiapine, risperidone, aripiprazole, and ziprasidone were more likely to report being hospitalized than users of other AAPs. Given that the FAERs database only contains spontaneous reports of AEs experienced by persons exposed to a drug but without information on exposed persons who did not have an event, a cohort study comparing hospitalizations among new users of individual AAPs against each other is needed to delineate these safety signals further.
- |||||||||| FT03 - Racial/Ethnic Differences in Pharmacogenetics () - May 27, 2022 - Abstract #CINP2022CINP_222;
There was no difference in remoxipride, olanzapine, paliperidone and lurasidone...Frye’s group compared lithium and mood stabilizing anticonvulsants (MSA) treatment patterns in more contemporary cohorts including the Mayo Clinic Bipolar Disorder Biobank, University of Mississippi Medical Center (UMMC), and the NIH funded All of Us (AoU) Research Program. While study designs differed, the AA vs EA lithium utilization was less (Mayo: OR=0.30, p=0.06; UMMC: RR=0.56 (0.43-0.72)
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Rexulti (brexpiprazole) / Lundbeck, Otsuka, Caplyta (lumateperone) - Intra / Cellular Therapies
Retrospective data, Journal: Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - May 12, 2022
Second-generation antipsychotics do not only differ in their propensity to produce weight gain, but also in the shapes of their dose-response curves. This information is important for dosing decisions in clinical practice.
- |||||||||| iloperidone / Generic mfg.
Retrospective data, Journal: Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. (Pubmed Central) - May 8, 2022
"Moderate" confidence in the results was found for paliperidone-LAI 1-monthly, iloperidone-OS, fluphenazine-OS, brexpiprazole-OS, paliperidone-LAI 1-monthly, asenapine-OS, haloperidol-OS, quetiapine-OS, cariprazine-OS, and lurasidone-OS...This finding is of particular relevance for low- and middle-income countries and constrained-resource settings, where few medications may be selected. Results from this network meta-analysis can inform clinical guidelines and national and international drug regulation policies.
- |||||||||| lurasidone / Generic mfg.
The Effect of Lurasidone on Anhedonia in Adult Patients with Bipolar Depression (Palomino Ballroom 4-10) - May 6, 2022 - Abstract #ASCP2022ASCP_115;
P3
Improvement in both quality of life and functioning appeared to be largely mediated by improvement in anhedonia, indicating that the amelioration of patients’ pervasive inability to feel pleasure or take interest in their environment is an important therapeutic target. Clinicaltrials.gov identifier: NCT00868699 Supported by funding from Sunovion Pharmaceuticals, Inc.
- |||||||||| The Implication of Nonpsychiatric Medications in Serotonin Syndrome () - May 5, 2022 - Abstract #APA2022APA_1089;
S’s medications revealed that he was taking home medications of duloxetine 60 mg, lurasidone 40 mg, and controlled release morphine 60 mg, and medications started in the hospital of ondansetron, prochlorperazine, dronabinol, antibiotics, oxycodone, and famotidine...There have been other case reports of serotonin syndrome secondary to cyclobenzaprine in the literature. 2,3,4 It is critical to look beyond psychiatric medications when considering serotonin syndrome.
- |||||||||| Psychiatry and Prolactin—a Review of Literature () - May 5, 2022 - Abstract #APA2022APA_1023;
The ranking in order of Hyperprolactinemia presented by these authors: Paliperidone > Risperidone > Lurasidone > Ziprasidone > Iloperidone > Olanzapine > Asenapine > Placebo > Quetiapine > Aripiprazole...Cabergoline is preferable to Bromocriptine...Another type of treatment: Alternative and symptomatic management can also be attempted. Estrogens or testosterone for hypogonadism and/or decreased BMD, PDE5 inhibitors for erectile dysfunction, promoting healthy diet and physical exercise, avoiding tobacco and alcohol, for amenorrhea>6 months OCPs can be given to prevent osteoporosis, If low Vitamin D levels, then supplementation etc Psychiatrists need to work corroboratively with other specialties of Medicine and keep abreast of recent evidence base to manage this problem.
- |||||||||| lurasidone / Generic mfg.
Effect of Lurasidone on Anhedonia in Adult Patients With Bipolar Depression () - May 5, 2022 - Abstract #APA2022APA_894;
The results of this post-hoc analysis suggests that lurasidone is an effective treatment for anhedonia in patients with a diagnosis of bipolar I disorder who present with moderate-to-severe major depressive episodes. Improvement in both quality of life and functioning appeared to be largely mediated by improvement in anhedonia, indicating that the amelioration of patients’ pervasive inability to feel pleasure or take interest in their environment is an important therapeutic target.
- |||||||||| lurasidone / Generic mfg.
A Case of Lurasidone Induced Urinary Retention () - May 5, 2022 - Abstract #APA2022APA_321;
Lurasidone is particularly notable for its strong antagonism of the 5-HT7 serotonin receptor. There is growing evidence that this receptor is involved in the promotion of micturition and voiding efficiency.
- |||||||||| Advances in the Treatment of Mood Disorders: Problems and Promises (Rooms 283-285 , Ernest N. Morial Convention Center) - Apr 26, 2022 - Abstract #APA2022APA_297;
Moreover, an oral form of the drug, zuranolone now has also shown efficacy in this very serious mood disorder...Finally Stephen Strakowski will discuss the current state of treating bipolar disorder, both mania and depression, including recent studies of cariprazine, lurasidone and lumateperone. He will also describe the current efficacy and safety data with mood stabilizers and the need for the development of novel treatments.
- |||||||||| Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie, Caplyta (lumateperone) - Intra / Cellular Therapies
8036: Bipolar Depression: Outcome and Pharmacological Treatment ([VIRTUAL]) - Apr 26, 2022 - Abstract #APA2022APA_266;
Finally, the use of antidepressants in bipolar depression remains controversial, especially as monotherapy, however in combination with mood stabilizers or atypical antipsychotics they appear to be a treatment option. Risk factors for antidepressants causing emerging symptoms of mania have been identified.
- |||||||||| Cyclurad (cycloserine/lurasidone) / NeuroRx
Phase classification, Enrollment change, Trial completion date, Trial primary completion date: MBD: NRX101 for Bipolar Depression and Sub-acute Suicidal Ideation and Behavior (clinicaltrials.gov) - Mar 31, 2022
P2, N=70, Not yet recruiting,
No abstract available Phase classification: P2/3 --> P2 | N=150 --> 70 | Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jun 2022 --> Dec 2022
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka
Preclinical, Journal: Effect of Novel Antipsychotics on Energy Metabolism - In Vitro Study in Pig Brain Mitochondria. (Pubmed Central) - Mar 25, 2022
The mitochondrial effects of novel antipsychotics might contribute on their adverse effects, which are mostly related to decreased ATP production and increased ROS production, while MAO-A inhibition might contribute to their antidepressant effect, and brexpiprazole- and loxapine-induced MAO-B inhibition might likely promote neuroplasticity and neuroprotection. The assessment of drug-induced mitochondrial dysfunctions is important in development of new drugs as well as in the understanding of molecular mechanism of adverse or side drug effects.
- |||||||||| lurasidone / Generic mfg.
Journal: Perinatal use of lurasidone for the treatment of bipolar disorder. (Pubmed Central) - Mar 24, 2022
Despite the decrease in lurasidone to the preconception dose post-delivery, the concentrations were higher postpartum compared to pregnancy. The decrease in lurasidone serum concentrations during pregnancy may increase the risk of worsening BD symptoms and suggests the need for determination of whether therapeutic monitoring and dose titration during pregnancy decreases illness exacerbation.
|
